Abstracts tagged "comparative effectiveness"

Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…
Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Javier Marrugo¹, Maude Bonin¹, Gilles Boire¹, Louis Bessette² and Ariel Masetto¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…
Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, Mary Ellen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Marc Natter¹¹ and The STOP-JIA CARRA Registry Investigators¹², ¹Hackensack University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Boston Children's Hospital, Boston, MA, ¹²Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1072 • ACR Convergence 2021
The Multidisciplinary Approach with Patient Collaboration Improve the Clinical Effectiveness of the Intervention
Carlos González¹, Luis Menchén-Viso¹, Ofelia Baniandres-Rodriguez¹, Carmen Lobo-Rodríguez¹, Ana Herranz-Alonso¹, Ignacio Marín-Jiménez¹, Juan Carlos Nieto², Lucia Ibares-Frias¹, Indalecio Monteagudo¹, Esther Chamorro de Vega¹, Javier Torresano-Bruno¹, Amparo Lopez-Esteban¹, Arantza Ais-Larisgoitia¹, Paloma Morales de los Ríos Luna¹, ana Lopez-Calleja¹, Sonia Garcia de San Jose³ and Jose Maria Alvaro-Gracia³, ¹CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Maranón, Madrid, Spain
Background/Purpose: We have developed a multidisciplinary unit for patients in treatment with biological therapies (BT) with the collaboration of Dermatology (Der), Gastroenterology (GE), Rheumatology (Rheu),…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1248 • ACR Convergence 2021
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Janet Pope¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, James Signorovitch³, Henry Lane³, Ha Nguyen³ and Philip Conaghan⁵, ¹University of Western Ontario, London, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Previous studies have found differential treatment efficacy of abatacept (ABA) for the treatment of RA based on biomarker-seropositivity.1-4 An earlier study found a differential…
Abstract Number: 1160 • ACR Convergence 2020
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
Aleksander Lenert¹, T. Shawn Sato², Sedat G Kandemirli¹, Patrick Ten Eyck¹ and Polly Ferguson³, ¹University of Iowa, Iowa City, IA, ²University of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Runsheng Wang¹, Abhijit Dasgupta² and Michael Ward³, ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²NIAMS, Bethesda, ³National Institutes of Health, Bethesda, MD
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…
Abstract Number: 1351 • ACR Convergence 2020
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
Lars Erik Kristensen¹, Masato Okada², William Tillett³, Soyi Liu-Leage⁴, Celine El Baou⁵, Andrew Bradley⁵, Gabriella Meszaros⁴ and Kurt de Vlam⁶, ¹The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ²St. Luke's International University, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ³Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁶Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium
Background/Purpose: Ixekizumab (IXE), a selective interleukin-17A antagonist, is approved for the treatment of active PsA, moderate-to-severe psoriasis (PsO), and radiographic/non-radiographic axial SpA in adults. The…
Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Yukiko Kimura¹, George Tomlinson², Laura Schanberg³, Mary Ellen Riordan⁴, Anne Dennos⁵, Vincent Del Gaizo⁶, Katherine Murphy⁷, Pamela F. Weiss⁸, Brian Feldman⁹ and Sarah Ringold¹⁰, ¹Hackensack Meridian School of Medicine, Hackensack, NJ, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³Duke University Medical Center, Durham, NC, ⁴Hackensack University Medical Center, Westwood, NJ, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Lousiana Department of Public Health, New Orleans, LA, ⁸Children's Hospital of Philadelphia, Philadelphia, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Seattle Children's, Seattle, WA
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
Abstract Number: 0010 • ACR Convergence 2020
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
Michael Putman¹, Yu Pei Eugenia Chock², Herman Tam³, Alfred Kim⁴, Sebastian Sattui⁵, Francis Berenbaum⁶, Maria (Maio) Danila⁷, Peter Korsten⁸, Catalina Sanchez Alvarez⁹, Jeffrey Sparks¹⁰, Laura Coates¹¹, Candace Palmerlee¹², Andrea Pierce¹³, Arundathi Jayatilleke¹⁴, Sindhu Johnson¹⁵, Adam Kilian¹⁶, Jean Liew¹⁷, Larry Prokop⁹, Hassan Murad⁹, Rebecca Grainger¹⁸, Zachary Wallace¹⁹ and Ali Duarte-Garcia⁹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Greenwich, CT, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Washington University School of Medicine, St. Louis, MO, ⁵Hospital for Special Surgery, New York, NY, ⁶Sorbonne Universit�, Paris, France, ⁷University of Alabama at Birmingham (UAB), Birmingham, AL, ⁸University Medical Center Göttingen, Gottingen, Germany, ⁹Mayo Clinic, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Oxford, Oxford, United Kingdom, ¹²12. Patient Research Partner, Berkeley, CA, ¹³Patient Research Partner, New York City, ¹⁴Lewis Katz School of Medicine, Temple University, Philadelphia, PA, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶George Washington University, Washington, DC, ¹⁷University of Washington, Seattle, WA, ¹⁸University of Otago, Wellington, New Zealand, ¹⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. There has been particular interest in the antimalarial agent…
Abstract Number: 0581 • ACR Convergence 2020
A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
Jacquelyn Chou¹, Ervant Maksabedian², David Collier³ and Howard Thom⁴, ¹PRECISION heor, Los Angeles, CA, ²Amgen Inc., LOS ANGELES, CA, ³Amgen, Thousand Oaks, CA, ⁴University of Bristol, Bristol, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].